# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

> **NCT03603431** · PHASE1 · COMPLETED · sponsor: **miRagen Therapeutics, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** MRG-110
- **DRUG:** Placebo
- **DRUG:** MRG-110
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03603431
- **Lead sponsor:** miRagen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2019-03-13
- **Final completion:** 2019-03-13
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603431, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03603431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*